中华网财经
2022.06.22 09:28

核心产品业绩承压,君实生物募资 40 亿研发新药

此次定增预案显示,JS001(特瑞普利单抗)投资金额 9.33 亿元,拟使用募资金额 8.6 亿元,是最大的开发项目之一。

The copyright of this article belongs to the original author/organization.
The current content only represents the author’s point of view, and has nothing to do with the position of Longbridge. The content is for investment reference only and does not constitute any investment advice. If you have any questions or suggestions about the content services provided by Longbridge, please contact: editorial@longbridge.global

Like